AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04823091
Drug: Fludarabine + Cyclophosphamide + CAR7-T Cells
RxNorm normalized name: CD4CAR T cells
DrugBank: Anti-CD4 CAR T-cell therapy (DB17281)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fludarabine 30 mg/kg on day -5, -4, and -3; cyclophosphamide 250 mg/kg on day -5, -4, and -3; CAR7-T Cells on day 0.
Trial: NCT06555640
Drug: DR10624 Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: DR10624 injection
Trial: NCT06555640
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: placebo
Trial: NCT04918173
Drug: Atenativ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antithrombin concentrate
Trial: NCT05230771
Drug: Chemotheraoy along
RxNorm normalized name: long pepper extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients receive only the prescribed chemotherapy.
Trial: NCT05628311
Drug: IBI362
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IBI362 administered subcutaneously (SC) once a week.
Trial: NCT06520904
Drug: PCSK9 inhibitor
RxNorm normalized name: PCSK9 inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCSK9 inhibitors combined with moderate-intensity statin therapy
Trial: NCT05902000
Drug: Intraoperative Drug Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tirofiban is used as an adjunct to endovascular therapy. The currently recommended dosing regimen is a combined intra-catheter arterial administration of a loading dose of 0.4 μg/(kg-min) for 30 min (total dose not to exceed 1 mg)， followed by intravenous pumping of 0.1μg/(kg-min) for 24-48h, and adjustment of dosing in conjunction with CT.
Trial: NCT05633810
Drug: Aspirin Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: non-enteric-coated tablet taken twice daily.
Trial: NCT04775459
Drug: Surfactant administration until 2020
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surfactant is administrated if Fi02 \>30% among the Guidelines of 2019
Trial: NCT04775459
Drug: Surfactant administration since 2021
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surfactant is administrated if Fi02 \>30% OR if score LUS \>8/18 among the literature
Trial: NCT06404463
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxorubicin, a widely used chemotherapy drug, belongs to the anthracycline class and is effective against various cancers, including breast cancer, leukemia, and sarcomas. It works by intercalating with DNA and inhibiting topoisomerase II, leading to DNA damage and disruption of DNA replication and transcription processes within cancer cells. Despite its efficacy, doxorubicin may cause side effects such as cardiotoxicity and bone marrow suppression, limiting its long-term use in some patients.
Trial: NCT06404463
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide is a chemotherapy medication commonly used to treat various types of cancers, including lymphoma, leukemia, and breast cancer. It belongs to the class of alkylating agents and works by crosslinking DNA strands, which prevents cell division and leads to cell death. While effective in treating cancer, cyclophosphamide can also cause side effects such as nausea, vomiting, and suppression of the immune system.
Trial: NCT06237231
Drug: DIT112
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DIT112 tablet
Trial: NCT06237231
Drug: DIT112 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DIT112 placebo tablet
Trial: NCT05034874
Drug: IXT-m200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IXT-m200 binds METH with high selectivity and affinity. The product contains a murine METH-binding variable region and the constant domains of a human immunoglobulin G (IgG) 2κ. This antibody isotype was chosen because of the lower risk of immune response compared to an IgG1 or IgG3. IXT-m200 targets METH, does not rely on binding to any endogenous target for its action, and has been well-tolerated in previous clinical studies.
Trial: NCT04994106
Drug: AZD5462
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive AZD5462, at dose levels of 1 to 5 in part A and at 1 to 4 in part B, respectively.
Trial: NCT05283954
Drug: Combination regimen: Fluoxetine, Prednisolone, Ivermectin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive the following treatments:~Fluoxetine 20 mg oral tablets: One tablet right after randomization (Day 0) followed by one daily tablet for the following 09 days.~Prednisolone 25 mg oral tablets: One tablet right after randomization (Day 0) followed by one daily tablet for the following 04 days.~Ivermectin 3 mg oral tablets: Tablets started right after randomization (Day 0; 400mcg/ kg dosing), administered once a day for 05 consecutive days.
Trial: NCT04978779
Drug: VIP152
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly IV infusion for 28 day cycles.
Trial: NCT04978779
Drug: BTKi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taken per local prescribing information
Trial: NCT04710329
Drug: Ascorbic acid
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The daily administration of 6 grams of vitamin C intravenously in 4 equal doses every 6 hours occurred and the treatment lasted 96 hours. Vials containing 1.5 gr vitamin C were placed in 100 cc 5% dextrose and infused intravenously in 30-60 minutes. Prepared serum bottles and sets are wrapped with aluminum foil in order to protect them from sunlight.
Trial: NCT05623592
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 17,5/15/10 mg Methotrexate subcutaneously
Trial: NCT05269290
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered once a day on top of standard therapy.
Trial: NCT05509023
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous administration of Placebo
Trial: NCT05054725
Drug: RMC-4630
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RMC-4630 administered orally as a capsule
Trial: NCT00002033
Drug: AS-101
RxNorm normalized name: OXT-101
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04991298
Drug: Oral premedication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral anesthesia premedication for congenital Cardiac surgery
Trial: NCT05719467
Drug: Buscopan 20 MG/ML Injectable Solution
RxNorm normalized name: Buscopan 20 MG/ML Injectable Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mL intravenously
Trial: NCT05719467
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4g orally
Trial: NCT05719467
Drug: Nacl 0.9%
RxNorm normalized name: DEXTROSE 5%/NACL 0.9% INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mL intravenously
Trial: NCT05428696
Drug: ALXN2080
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Powder-in-capsule
Trial: NCT05428696
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Powder-in-capsule
Trial: NCT00002147
Drug: Doxorubicin hydrochloride (liposomal)
RxNorm normalized name: DOXORUBICIN HYDROCHLORIDE LIPOSOME
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05395416
Drug: HEC74647PA+HEC110114
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administered orally once daily for 12 weeks
Trial: NCT05395416
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administered orally once daily for 12 weeks
Trial: NCT05624424
Drug: Sufentanil
RxNorm normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Anesthesia was induced with Sufentanil 0.3\~0.5 ug/kg by intravenous injection after the LoC and BIS\<60.
Trial: NCT05624424
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: After the LoC, remifentanil 0.1\~0.3 ug/kg/min inject intravenously until the end of surgery.
Trial: NCT04492436
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weight based dose of reconstituted treatment administered through intravenous drip infusion on Day1 of each chemotherapy cycle
Trial: NCT05187715
Drug: Simvastatin 40mg
RxNorm normalized name: SIMVASTATIN 40MG TAB
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simvastatin 40mg OD
Trial: NCT04971512
Drug: Placebo (Part 2)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match EDP-721 (Part 2)
Trial: NCT04971512
Drug: Placebo (Part 2)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match EDP-514
Trial: NCT00001058
Drug: Clarithromycin
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT06408519
Drug: Ibuprofen 400 mg
RxNorm normalized name: ibuprofen 400 MG
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen pills 3x/day
Trial: NCT06139133
Drug: Placebo supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT06561542
Drug: LX22001 for Injeciton
RxNorm normalized name: gentamicin
DrugBank: Gentamicin (DB00798)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: single dose: 25mg,50mg,100mg,200mg ,intravenous infusion. repeat doses: 50mg,100mg , intravenous infusion,once daily for 3 days.
Trial: NCT05763550
Drug: HSK16149 20mg BID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HSK16149 20mg, orally twice a day, treatment period; 4-weeks fixed dose.
Trial: NCT05763550
Drug: HSK16149 40mg BID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HSK16149 40mg, orally twice a day, treatment period; 4-weeks fixed dose.
Trial: NCT04920695
Drug: Nitric Oxide
RxNorm normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pulmonary vasodilator (gas).
Trial: NCT04920695
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: medical grade normoxic gas (FiO2 = 0.21)
Trial: NCT05174754
Drug: Best Medical Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Best medical therapy with biologic agent or small-molecule therapy
Trial: NCT06291207
Drug: AD-224A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PO, Once daily, 8weeks
Trial: NCT06291207
Drug: AD-224B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PO, Once daily, 8weeks
Trial: NCT06291207
Drug: AD-224C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PO, Once daily, 8weeks
Trial: NCT06291207
Drug: Placebo of AD-224A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PO, Once daily, 8weeks
Trial: NCT06291207
Drug: Placebo of AD-224B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PO, Once daily, 8weeks
Trial: NCT06291207
Drug: Placebo of AD-224C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PO, Once daily, 8weeks
Trial: NCT06536400
Drug: HSK42360
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration, QD
Trial: NCT04881123
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosage Level(s): Matched placebo (1 capsule twice a day - morning and evening) (except on Day 168 where participants will only receive a single dose (QD) in the morning)
Trial: NCT04701216
Drug: SHR8735
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR8735 is an thrombopoietin receptor agonist to promote platelet production.
Trial: NCT05109104
Drug: CAP UnScented
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sunscreen lip balm.
Trial: NCT05109104
Drug: CAP Herbal Mint
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunscreen lip balm.
Trial: NCT05109104
Drug: CAP Mountain Berry
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunscreen lip balm.
Trial: NCT05109104
Drug: SPF Standard Sunscreen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SPF Standard (7 percent \[%\] Padimate-O and 3% Oxybenzone)
Trial: NCT04853875
Drug: Tetracycline, Metronidazole, Bismuth subcitrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 52 participants (Group A) are randomly assigned to receive intraluminal eradication of H. pylori with medicament containing Tetracycline, Metronidazole, and Bismuth subcitrate
Trial: NCT04853875
Drug: Amoxicillin, Metronidazole, Clarithromycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 52 participants (Group B) are randomly assigned to receive intraluminal eradication of H. pylori with medicament containing Amoxicillin, Metronidazole, and Clarithromycin
Trial: NCT06348888
Drug: BAY2927088
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT04848688
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monotherapy, oral administration, single dose, matching number of tablets to either moxidectin or ivermectin
Trial: NCT05264896
Drug: 5-FU, Leucovorin, Oxaliplatin, Docetaxel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FLOT 4 cycles pre and post radical gastrectomy
Trial: NCT05264896
Drug: XELOX
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: XELOX 8 cycles post radical gastrectomy
Trial: NCT06089395
Drug: Jiajian Guishen granules
RxNorm normalized name: chlorpheniramine maleate / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Guiaphen HD]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This study was a stratified district group randomized, double-blind, double simulation, positive control clinical trial with JJGS granules + coenzyme Q10 simulant in the test group and JJGS granules simulant + coenzyme Q10 in the control group
Trial: NCT01172249
Drug: Glucosamine sulfate + chondroitin sulfate - MANTECORP
RxNorm normalized name: chondroitin sulfates / glucosamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 capsule three times daily before meals (glucosamine sulfate 500 mg + sodium chondroitin sulfate 400 mg).
Trial: NCT01172249
Drug: Glucosamine sulfate + chondroitin sulfate - CONDROFLEX
RxNorm normalized name: chondroitin sulfates / glucosamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 capsule three times daily before meals (glucosamine sulfate 500 mg + sodium chondroitin sulfate 400 mg).
Trial: NCT05526703
Drug: D064, D701, placebo of D012
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental Group Subjects assigned to this group are treated with D064, D701, placebo of D012
Trial: NCT05526703
Drug: D012, placebo of D064, placebo of D701
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparator Group Subjects assigned to this group are treated with D012, placebo of D064, placebo of D701
Trial: NCT06557603
Drug: Soolantra ® (Ivermectin) cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: \[1 gm ± 0.030 gm\] of product was applied in a thin layer over the entire face (avoiding the eyes, lips, and mucous membranes).
Trial: NCT06392126
Drug: nL-CHCHD-001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Personalized antisense oligonucleotide
Trial: NCT04968951
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment
Trial: NCT00002120
Drug: Leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT05083637
Drug: L- carnitine oral solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The L-carnitine syrup formulation will be provided to study participant at nutritional rehabilitation unit (NRU) under controlled set-up
Trial: NCT05010460
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: orally 100mg every other day for 5-8 days prior to CABG
Trial: NCT05366231
Drug: Kesuting syrup
RxNorm normalized name: omega-3 acid ethyl esters (USP)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment + Kesuting Syrup, take orally, 20 ml once, three times a day.Conventional treatment refer to Diagnosis and Treatment Protocol for COVID-19 (Trial Version 9 or later). Except for the test drugs, during the observation period, it is prohibited to use other Chinese and Western medicines for cough and phlegm elimination for treatment. If combined use is required, it shall be recorded truthfully.
Trial: NCT05366231
Drug: LianHuaQingWen Granules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment + LianHuaQingWen Granules, orally, 1 bag at a time, 3 times a day.Conventional treatment refer to Diagnosis and Treatment Protocol for COVID-19 (Trial Version 9 or later).Except for the test drugs, during the observation period, it is prohibited to use other Chinese and Western medicines for cough and phlegm elimination for treatment. If combined use is required, it shall be recorded truthfully.
Trial: NCT00415935
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04773405
Drug: a 1: 1 mixture of 2% lidocaine with 5ug/ml epinephrine and 0.5% levobupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This study adopts a Modified Narayana rule (MNR), a sequential up-and-down pharmacodynamics method (UDM) to estimate the minimum effective local anesthetic volume of 90% (MELAV90) of cases of the aforementioned local anaesthetic (LA) mixture, in order to produce the surgical anaesthesia of the whole upper extremity of the patients scheduled for upper limb surgeries. Based on the principal investigator's clinical experience, the initial volume of 21ml will be used. Depending on the success or failure of the SeTB, which is defined as the readiness for surgery at 30 minutes after the block, the volume for the next patient will be adjusted up or down by 3ml (1ml for each trunk of brachial plexus located above the clavicle). The upper dose limit of the study to minimize the potential for local anaesthetic systemic toxicity will be 30ml and the lower dose limit will be 12ml, which will be of no clinical importance.
Trial: NCT05068284
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) infusion; Subcutaneous Injection
Trial: NCT05068284
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous Injection
Trial: NCT04773600
Drug: Vehicle cream
RxNorm normalized name: vehicle cream base no.160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle cream for topical application
Trial: NCT05621252
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo
Trial: NCT05633420
Drug: Pyramax
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participant body weight~* ≥65 kg (Pyramax 4 tablets)~* ≥45 kg and \<65 kg (Pyramax 3 tablets)
Trial: NCT03864094
Drug: Norepinephrine
RxNorm normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0,1 microg/kg
Trial: NCT03864094
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1,7 microg/kg
Trial: NCT05809180
Drug: Pro-miniCHOP-like regimen
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rituximab 375mg/m2 ivgtt d1; orelabrutinib 150mg per day oral administration till progresses or intolerant toxicity; pomalidomide 4mg d1-7; cyclophosphamide 400mg/m2 ivgtt d2; doxorubicin 25mg/m2 ivgtt d2/ doxorubicin liposome 15 mg/m2 ivgtt d2; vindesine 2mg ivgtt d2; dexamethasone 10mg ivgtt d2-6.
Trial: NCT06245330
Drug: AST-001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: liquid formulation for Intravenous infusion
Trial: NCT05809180
Drug: R-miniCHOP-like regimen
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rituximab 375mg/m2 ivgtt d1; cyclophosphamide 400mg/m2 ivgtt d2; doxorubicin 25mg/m2 ivgtt d2/ doxorubicin liposome 15 mg/m2 ivgtt d2; vindesine 2mg ivgtt d2; dexamethasone 10mg ivgtt d2-6.
Trial: NCT06372223
Drug: SPH5030
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SPH5030 tablets：400mg,orally, Dosing in the fasted state followed by fed dosing.
Trial: NCT06372223
Drug: SPH5030
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SPH5030 tablets：400mg, orally, Dosing in the fed state followed by fasted dosing.
Trial: NCT05732454
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PART 1 DOUBLE BLIND Placebo - one table daily for up to 16 weeks
Trial: NCT03954483
Drug: Buspirone 10 Mg Oral Tablet
RxNorm normalized name: busPIRone 10 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orally administered prior to experiments.
Trial: NCT03954483
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orally administered prior to experiments.
Trial: NCT03249844
Drug: Methylprednisolone + prednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The experimental intervention consists of 5 consecutive days Methylprednisolone at a daily single intravenous dose of 20 mg/kg body-weight (max 1 g/day) followed by a 4-week course of tapering Prednisolone given at a daily single oral dose in the morning:~* week 1 and 2, oral Prednisolone 1 mg/kg/day (max 40 mg/day), ,~* week 3 and 4, oral Prednisolone 0,5 mg/kg/day (max 20 mg/day),
Trial: NCT04947761
Drug: modified Tian Wang Bu Xin Dan hydrogel patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: modified Cheonwangbosimdan hydrogel patch (one patch/24 hours) applied to Shenque point for 4 days (1 patch daily beginning 2 days preoperative, and continued at 1 patch daily until 2 days postoperatively)
Trial: NCT04755946
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT05369039
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Systemic corticosteroid
Trial: NCT06150560
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral capsules that contain no active drug ingredients administered orally once daily for 52 weeks.